Sidoti Csr Analysts Lower Earnings Estimates for USANA Health Sciences, Inc. (NYSE:USNA)

USANA Health Sciences, Inc. (NYSE:USNA) – Stock analysts at Sidoti Csr reduced their Q2 2024 earnings per share estimates for shares of USANA Health Sciences in a report issued on Wednesday, May 1st. Sidoti Csr analyst A. Lebiedzinski now anticipates that the company will post earnings of $0.62 per share for the quarter, down from their previous estimate of $0.67. The consensus estimate for USANA Health Sciences’ current full-year earnings is $2.75 per share. Sidoti Csr also issued estimates for USANA Health Sciences’ Q3 2024 earnings at $0.64 EPS, Q4 2024 earnings at $0.68 EPS, FY2024 earnings at $2.80 EPS, Q1 2025 earnings at $0.86 EPS, Q2 2025 earnings at $0.79 EPS, Q3 2025 earnings at $0.86 EPS and Q4 2025 earnings at $0.88 EPS.

A number of other equities research analysts have also recently weighed in on the company. StockNews.com upgraded USANA Health Sciences from a “buy” rating to a “strong-buy” rating in a report on Friday, January 12th. DA Davidson reduced their target price on USANA Health Sciences from $53.00 to $48.00 and set a “neutral” rating on the stock in a research note on Thursday, February 22nd.

USANA Health Sciences Trading Down 3.3 %

NYSE USNA opened at $45.55 on Thursday. The business’s 50 day moving average is $46.62 and its two-hundred day moving average is $48.36. USANA Health Sciences has a 12-month low of $41.45 and a 12-month high of $69.60. The stock has a market capitalization of $876.38 million, a price-to-earnings ratio of 14.19, a PEG ratio of 1.38 and a beta of 0.94.

USANA Health Sciences (NYSE:USNA) last posted its quarterly earnings data on Tuesday, February 6th. The company reported $0.87 EPS for the quarter, beating the consensus estimate of $0.52 by $0.35. The firm had revenue of $221.08 million during the quarter, compared to the consensus estimate of $206.70 million. USANA Health Sciences had a return on equity of 12.80% and a net margin of 6.88%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of USNA. CWM LLC boosted its holdings in shares of USANA Health Sciences by 21.8% in the first quarter. CWM LLC now owns 1,543 shares of the company’s stock valued at $75,000 after acquiring an additional 276 shares in the last quarter. New York State Common Retirement Fund grew its position in USANA Health Sciences by 1.2% in the fourth quarter. New York State Common Retirement Fund now owns 24,500 shares of the company’s stock worth $1,313,000 after buying an additional 279 shares during the last quarter. Swiss National Bank grew its position in USANA Health Sciences by 1.2% in the third quarter. Swiss National Bank now owns 25,500 shares of the company’s stock worth $1,495,000 after buying an additional 300 shares during the last quarter. Rhumbline Advisers grew its position in USANA Health Sciences by 1.4% in the third quarter. Rhumbline Advisers now owns 34,942 shares of the company’s stock worth $2,048,000 after buying an additional 496 shares during the last quarter. Finally, Strs Ohio grew its position in USANA Health Sciences by 4.8% in the third quarter. Strs Ohio now owns 10,900 shares of the company’s stock worth $638,000 after buying an additional 500 shares during the last quarter. Institutional investors own 54.25% of the company’s stock.

Insider Transactions at USANA Health Sciences

In related news, insider David Mulham Mulham sold 4,311 shares of the firm’s stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $47.76, for a total transaction of $205,893.36. Following the completion of the sale, the insider now directly owns 7,825 shares of the company’s stock, valued at approximately $373,722. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In other news, insider David Mulham Mulham sold 4,311 shares of the company’s stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $47.76, for a total value of $205,893.36. Following the sale, the insider now owns 7,825 shares in the company, valued at approximately $373,722. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Daniel A. Macuga sold 3,791 shares of the company’s stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $47.14, for a total transaction of $178,707.74. The disclosure for this sale can be found here. Insiders sold 28,598 shares of company stock valued at $1,379,499 over the last quarter. Company insiders own 0.33% of the company’s stock.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.